Leap 35% objective response rate in colorectal cancer trial initial data

 35% objective response rate (ORR) in second-line colorectal cancer (CRC) patients treated with sirexatamab (DKN-01) plus bevacizumab and chemotherapy, compared to 23% ORR in the control arm

DKK1 levels highly correlated with clinical activity in CRC population

ORR benefit with sirexatamab observed across multiple potential Phase 3 CRC populations

Preparations will begin for a registrational Phase 3 study in second-line CRC patients

DisTinGuish Part C study in gastric cancer demonstrates activity in biomarker populations, but not the signal necessary to advance into Phase 3

Leap to host a conference call to present clinical data today, January 28, 2025, at 8:00 a.m. ET

Leap's management team will host a conference call today, January 28, 2025 at 8:00 a.m. Eastern Time to further discuss the data. The conference call will be broadcast live in listen-only mode and can be accessed via the webcast URL: https://edge.media-server.com/mmc/p/t93pn2ke. A replay of the event will be available for a limited time on the Investors page of the Company's website at https://investors.leaptx.com/. 

https://www.prnewswire.com/news-releases/leap-therapeutics-reports-initial-clinical-data-from-part-b-of-the-defiance-study-and-part-c-of-the-distinguish-study-302361609.html